With Jevtana Approved For Advanced Prostate Cancer, Sanofi Could See Expansion To First-Line Use

Sanofi-Aventis gained a fast approval for its chemotherapy Jevtana (cabazitaxel) - just 11 weeks after the final filing in a rolling submission for second-line treatment of advanced hormone-refractory prostate cancer. But the company is also positioned for a quick expansion to the first-line setting